Bionity is an independent consulting firm located in Budapest, Hungary that focuses on providing valuation, financial, intellectual property, market analysis, and licensing services to biotech, pharma, medtech companies, investors, and academic institutions. It focuses on areas like drug development, medical devices, diagnostics, manufacturing, and bioinformatics. The managing director has over 15 years of experience in the life sciences sector in areas like corporate finance, investment promotion, and business development.

1. Corporate Overview

2. Corporate Overview
 BIONITY is an independent consulting
firm focusing on complex valuation,
financial-, IPR consultancy, market
analysis and licensing.
Budapest
 We provide our services mainly to
biotech-, pharma-, medtech companies,
life sciences focused investors and
academic research institutions.
 Our office is located in Budapest,
Hungary, with a broad activity in CEE.
|

3. Our Industry Focus:
Life Sciences
1.
 PreClinical / Clinical Stage Drug Development Projects
 Platform & Drug Delivery Technologies
2.
 Medical Device Developments
 Diagnostics & Analytical Technologies
3.
 CROs & SMOs
 BioInformatics
4.
 Development of API & Biological Manufacturing
Capacities
|

4. Partnerships and Membership
eckel & partners exhibit decades of local and international Cogito Consuiting is an IPR and technology valuation
industry experience on executive level. eckel & partners specialist consulting firm located in Budapest. Its
provides pragmatic business development and marketing expertise include novelty, patentability, FTO analysis and
services to Pharma, Biotech and other health care strategic IPR consulting. Cogito is also supporting its
companies. Their team and associates are transaction- clients with evaluation of the market potential of new
orientated and help our clients to create incremental value technologies.
through Partnering and M&A on an international scale.
www.eckelpartners.com www.cogitoconsuling.eu
The Hungarian Biotechnology Association (HBA) was established by Hungary's
leading human biotechnology companies with the aim of promoting the
development and representation of the Hungarian biotechnology sector.
www.hungariabiotech.org
|

5. |

6. Technology Assessment
A combination of patentability, freedom to operate and market
opportunities has to be taken into account when an invention originating
from university research is examined for a decision on commercialization.
We are supporting TTOs and Incubator Houses in the initial assessment
of novelty, market potential, in the elaboration of a business strategy and
in the development all the way to involve Seed Money and/or Business
Angels into the project.
 Novelty and patentability analysis
 Freedom-to-operate analysis
 Evaluation of market potential
 IP Analysis and IPR Strategy
|

7. Pipeline Review and Valuations
Our expertise in financial valuation combined with our strategic partners -
specialized in legal, regulatory affairs & IPR - opens the door to a
comprehensive and sound review of your pipeline.
 Value of each project scenario
 Value of pipeline
 Risk profile of pipeline
 Sales forecasts of each project (worst case, base case, best case)
 Value development of each project
 Value development of the pipeline
 Scenario analysis
|

8. Investment & Market Analysis
We support you with our valuation and due diligence to get this insight
before you commit your money into new R&D projects. A market analysis
can be combined with competitor and product surveillance.
 SWOT, Five Forces Analysis of your company and projects
 Terry Hill Analysis of operations
 Desk researches about competitive landscape and market potentials
 Analysis of the Probabilities of Success
 Evaluation of Peak Sales dynamics, volatility, elasticity with different
scenarios
|

9. Creating Spin-Outs
Supporting holding companies and TTOs to make ROI on promissing
project and create a realistic business model and achievable plans.
Setting-up transparent business terms is fundamental for the proper
functioning of outperforming growth of Spin-outs.
 Specific factors to the Founders, Shareholders, Inventors.
 Legal advice on ownership structure of the Spin-out company
 Involving external partners, Coaches, Venture advisors into Spin-off
|

10. Raising Capital
Our strong network with Life Sciences focused VCs , CVCs and HNWIs is
prerequested to reach and meet suitable investor(s) corresponding to
your financial needs, pipeline and stage of development.
 Reviewing the Teaser and Company Presentation
 Elaboration of Mid-term individual financial Strategies
 Defining and continously updateing the „Investors List”
 Planning and organizing one-on-one meetings with potential investors
 Structuring the Term Sheet and assisting on the Due Diligence process
 Corporate restructuring and Corporate governance related to deals
|

11. Financial Planning
The discount rate for the valuation is elaborated for each company
individually based on our sound model that takes into account the
development stage of the pipeline projects, IP positions, indications, risk,
operating costs and the strategy of the Company.
 CashFlow Analysis
 Profit and Loss Statements (P&L)
 Risk-Adjusted Net Present Value Calculations (rNPV)
 Real-Options Valutions (ROV)
 Deal-Sourcing and Pre-Selection Services for professional Investors
|

12. Licensing and Partnering
For a BioPharma company, securing IPR and exploiting such rights by
licensing/partnering constitute some of the most fundamental aspects of
the business. We help define which rights should be licensed and what
type of license should be granted.
 Developing Licensing Strategy (Upfront, Milestone, Royalty payments)
 License contract value for licensee and licensor (rNPV, Real Options)
 IRR for licensee and licensor (rNPV and Real Options)
 Value share between licensor and licensee
 Identifying and contacting potential license partners
 Implementing, negotiating and managing License-In & Out deals
 Advising on Term Sheets and Licensing Agreements
|

13. FDI Promotion
Hungarian life sciences sector is characterized with highly skilled
workforce, stable political and regulatory system & strong governmental
commitment. Whether it is a specialized R&D unit or a large greenfield
manufacturing plant, we help you to find the rigth local partnes and ideal
location.
 Market intelligence;
 Feasibility studies on foreign direct investments;
 Academic match-making;
 Site Evaluation and pre-selection services;
 Negotiation with investment promotion agencies;
 Supporting investors to obtain setting-up permissions on fast-track;
|

14. Professional Background
Before founding Bionity R&D Investment Advisors in 2007, he was the director of the CEE
activities at PCA Capital Advisors (2005-2007), a Frankfurt based corporate finance butique
focusing on biotechnology and ICT financing. Before he held the position of “Head of Priority
Sectors” at the Hungarian Investment and Trade Development Agency, ITDH (2002-2005). He is
fluent in English and French. He is the Board Member of the Hungarian Biotechnology
Association and member of the SME Platform of EuropaBio.
 Marcell Veidner He is currently a fellow at the globally renowned Biotechnology MBA program of Instituto de
Managing director Empresa Business School (Madrid, Spain) and Harvard Business School (Boston, MA).
He has been graduating in economics at Budapest University of Economic Science and
+3620.284.9662 Administration with major in entrepreneurship, and also obtained Master degree in “European
marcell.veidner@bionity.eu Studies” at the same institution.
|

15. www.bionity.eu
info@bionity.eu
+36.20.284.9662
H-1036, Budapest
Perc u. 6.